The FDA has released 466 records under its CRL transparency program (openFDA, last updated 2026-11-18; snapshot read 2026-11-21). 1 of them repeats another record (same date, application numbers and text), leaving 465 distinct records. 452 are Complete Response Letters dated 2009 to 2026. Each count below says which files it comes from and how it is made, so anyone can redo it. Counts and date differences only: no approval rates, no predictions. Every letter, by year; every CRL, by company.
| Letter year | Complete Response Letters |
|---|---|
| 2026 | 39 |
| 2025 | 60 |
| 2024 | 67 |
| 2023 | 30 |
| 2022 | 25 |
| 2021 | 46 |
| 2020 | 36 |
| 2019 | 36 |
| 2018 | 32 |
| 2017 | 24 |
| 2016 | 20 |
| 2015 | 9 |
| 2014 | 7 |
| 2013 | 12 |
| 2012 | 3 |
| 2011 | 2 |
| 2010 | 2 |
| 2009 | 2 |
The release also holds 5 records typed with no letter type; 4 records typed Tentative Approval; 1 record typed Refusal To File; 1 record typed Corrected Provisional Determination; 1 record typed Provisional Determination; 1 record typed Rescind Complete Response. They are not counted as CRLs on this page.
165 Complete Response Letters dated 2024 or later have a PDF of their own. 163 of them have a text layer we read; 94 carry at least one deficiency section heading in the FDA's own words (labeling, safety update and other administrative sections set aside). The other 69 carry no deficiency heading that the extractor recognizes yet, so they are left out of the table rather than guessed; they are read again as its vocabulary grows. A letter can name several sections.
| Section family (the letter's own heading) | Letters, of 94 |
|---|---|
| Product quality or CMC | 52 |
| Facility inspections | 32 |
| Clinical or statistical | 22 |
| Clinical pharmacology | 11 |
| Nonclinical | 11 |
| Human factors or device | 8 |
| Microbiology (heading as written, not further specified) | 10 |
| REMS | 5 |
Headings are read from the PDF text layer only (extract_crl_headings.py), never from openFDA's OCR text.
81 applications (an original NDA or BLA, or one supplement) have two or more Complete Response Letters in the release; 24 have three or more. Grouped on the application number the FDA printed on each record; 2 letters the FDA later rescinded as issued in error are left out.
The 66 others are on the full list.
For 167 original NDAs, the FDA's Orange Book (products file, FDA files dated 2026-11-13) lists a first approval after the last Complete Response Letter in the release (rescinded letters left out). Days from that letter to that approval: median 423, middle half (quartiles) 298 to 680, shortest 49, longest 3623.
| Letter to approval | NDAs |
|---|---|
| under 1 year | 63 |
| 1 to 2 years | 71 |
| 2 to 3 years | 13 |
| 3 years or more | 20 |
Read this as a description of the released letters, not of CRLs in general: the FDA released its older letters for applications it had approved, and recent letters have had little time to resolve. BLAs are not in the Orange Book and are not counted. 3 NDAs whose earliest listed product predates the letter are left out. Shortest gaps:
| NDA | Product (Orange Book) | Last CRL | Approved | Days |
|---|---|---|---|---|
| 211321 | Nayzilam | March 29, 2019 | May 17, 2019 | 49 |
| 219122 | Brynovin | November 4, 2024 | January 16, 2025 | 73 |
| 211241 | Zycubo | September 30, 2025 | January 12, 2026 | 104 |
| 210821 | Tetracaine Hydrochloride | November 20, 2018 | March 12, 2019 | 112 |
| 211970 | Vyondys 53 | August 19, 2019 | December 12, 2019 | 115 |
openFDA's approval_status field says these 11 letters belong to applications not approved. The Orange Book lists each NDA as approved after the letter. Both are FDA files; the Orange Book lists each product as approved, and each approval it lists is dated before openFDA's last update (2026-11-18).
| NDA | Product | CRL | Orange Book approval |
|---|---|---|---|
| 218592 | Pixclara | April 25, 2025 | September 11, 2026 |
| 217379 | Cavhanza | June 14, 2024 | May 29, 2026 |
| 211241 | Zycubo | September 30, 2025 | January 12, 2026 |
| 217338 | Mucinex 12Hr Cold & Fever Multi-Symp | July 26, 2024 | December 22, 2025 |
| 218571 | Cardamyst | March 27, 2025 | December 12, 2025 |
| 212271 | Contepo | December 11, 2024 | October 22, 2025 |
| 217294 | Lasix Onyu | January 12, 2024 | October 7, 2025 |
| 215029 | Bondlido | July 11, 2024 | September 24, 2025 |
| 215244 | Forzinity | May 15, 2025 | September 19, 2025 |
| 218879 | Subvenite | January 3, 2025 | September 16, 2025 |
| 218698 | Lopressor | June 12, 2024 | August 28, 2025 |
NDA 202408, Fera Pharmaceuticals, LLC: a record typed "Rescind Complete Response" dated March 28, 2019 (PDF). It is not counted as a CRL above. It names the FDA's earlier letters on the application as issued in error; those letters stay in the yearly count, because they are in the release, and are left out of the repeat-CRL and letter-to-approval counts.
31 decision pages on this site carry the FDA's own released letter. Days from the letter's date (the FDA's stated action date, for a corrected letter) to the date our decision page is filed under:
| Days after the letter | Pages |
|---|---|
| 0 | 5 |
| 1 | 15 |
| 2 | 5 |
| 3 | 4 |
| 4 or more | 2 |
Four days or more: CING-2026-06-02 (4 days after the letter of May 29, 2026); RARE-2025-07-11 (4 days after the letter of July 7, 2025).
Inputs: the FDA's CRL release (openFDA transparency/crl, snapshot 2026-11-21), the section headings each PDF's text layer carries (_crl_headings.json), the Orange Book products file (_orange_book/products.txt), and this site's decision pages. The script is build_crl_facts.py in the site's public repository; it runs on every rebuild. A letter the FDA released twice (same date, application numbers and text) is counted once. Capricor's two CRLs for deramiocel, from the primary sources.